Fulcrum Therapeutics, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Fulcrum Therapeutics' 2025 annual report highlights promising Phase 1b pociredir data for sickle cell disease and a strengthened financial position, despite a significant net loss.
NASDAQ
10-K: Fulcrum Therapeutics Reports 2024 Results, Strategic Shift to SCD and Inherited Aplastic Anemias
Fulcrum Therapeutics announces its 2024 financial results and a strategic realignment focusing on pociredir for sickle cell disease and novel therapies for inherited aplastic anemias after suspending losmapimod development.
NASDAQ
Fulcrum Therapeutics, a clinical-stage biopharmaceutical company, reported its 2023 financial results and operational progress, highlighting advancements in its lead programs, losmapimod for FSHD and pociredir for SCD.